-
Mashup Score: 0Severe Alopecia Areata Patients Without Regrowth of Scalp Hair Benefit from Dose Increase of Baricitinib - 9 month(s) ago
This new data may need to be examined by health providers when they advise patients about treatment outcomes for increasing dosage, including those who could benefit from a higher dose of baricitinib.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
No statistically significant differences in retention rates were observed among those treated with baricitinib monotherapy or in combination with methotrexate.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
No statistically significant differences in retention rates were observed among those treated with #baricitinib monotherapy or in combination with methotrexate. https://t.co/beAn23M6c9 #RheumatoidArthritis
-
-
Mashup Score: 0Baricitinib produces mixed results in pair of BRAVE lupus trials - 1 year(s) ago
Baricitinib met the primary endpoint in one phase 3 study of patients with systemic lupus erythematosus, but failed to meet the same endpoint in a second trial aiming to repeat the results, according to data published in The Lancet.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
ICYMI: #Baricitinib met the primary endpoint in one phase 3 study of patients with systemic #lupus erythematosus, but failed to meet the same endpoint in a second trial aiming to repeat the results @EricFMorand @MonashUni @Monash_FMNHS #RheumTwitter https://t.co/WC1wR8Q0pn
-
-
Mashup Score: 0Baricitinib produces mixed results in pair of BRAVE lupus trials - 1 year(s) ago
Baricitinib met the primary endpoint in one phase 3 study of patients with systemic lupus erythematosus, but failed to meet the same endpoint in a second trial aiming to repeat the results, according to data published in The Lancet.
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
#Baricitinib met the primary endpoint in one phase 3 study of patients with systemic #lupus erythematosus, but failed to meet the same endpoint in a second trial aiming to repeat the results @EricFMorand @MonashUni @Monash_FMNHS #RheumTwitter https://t.co/WC1wR8Q0pn
-
-
Mashup Score: 1Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I) - 1 year(s) ago
The primary endpoint in this study was met for the 4 mg baricitinib group. However, key secondary endpoints were not. No new safety signals were observed.
Source: The LancetCategories: Latest Headlines, RheumatologyTweet-
NEW in @TheLancet—Two phase 3 trials of #baricitinib for systemic #lupus erythematosus #SLE-BRAVE-I > https://t.co/wX0w7w4Glm SLE-BRAVE-II > https://t.co/56sd0DmjN9 Linked Comment by Laura Durcan (@Rheum2improve) & Grainne Murphy > https://t.co/RBJYEcSNle https://t.co/XW6sXQnSn9
-
-
Mashup Score: 0
In his latest HCPLive interview, regarding a presentation at Winter Clinical Miami, Chovatiya spoke about recent JAK inhibitor developments, alopecia areata, baricitinib, and more.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
In an interview regarding his @fallclinical conference presentation, @RajMDPhD spoke about recent JAK inhibitor developments, #AlopeciaAreata, #baricitinib, and more. Check out the interview here: https://t.co/502V6sw6yc
-
-
Mashup Score: 0BRAVE Trials: 52-Week Baricitinib Data Demonstrate Continued Improvements in Alopecia Areata - 1 year(s) ago
The proportion of patients who achieved a SALT score < 10 jumped from 24.9% at 36 weeks to 28.9% at 52 weeks in the BARI 4-mg arm and 11.8% to 15.3% in the BARI 2-mg arm.
Source: Dermatology TimesCategories: Dermatology, Latest HeadlinesTweet-
Investigators at Winter Clinical Miami presented a poster on long-term safety and efficacy data from the BRAVE-AA phase 3 trials evaluating #baricitinib for patients with #AlopeciaAreata. #WCM23 @fallclinical https://t.co/zbME3mGVvu
-
-
Mashup Score: 0Rapid Response to Baracitinib Associated with Lower Baseline Clinical Disease Activity Index in Rheumatoid Arthritis Patients - 1 year(s) ago
Recent phase 3 clinical trial data explains response patterns of rheumatoid arthritis patients to baracitinib.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
#RheumatoidArthritis patients treated with 4 mg #baricitinib showed rapid response with a lower baseline CDAI score and had a gradual or limited response with a higher score. Read more here: https://t.co/JDqHljUCVc https://t.co/RRuvD4l1Rc
-
-
Mashup Score: 0Adjuvant Baricitinib, Topical Corticosteroids Show Long-term Efficacy in Moderate-to-Severe AD - 1 year(s) ago
Adult patients with moderate-to-severe atopic dermatitis (AD) in the phase 3 BREEZE-AD7 study showed sustained improvement of AD signs and symptoms after 68 weeks with combination treatment of bariticitinib and topical corticosteroids.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Adjuvant #Baricitinib, Topical Corticosteroids Show Long-term Efficacy in Moderate-to-Severe #AtopicDermatitis https://t.co/RQXe8gdSql https://t.co/4O5AYWSybR
-
-
Mashup Score: 0Advances to Alopecia Areata Treatment and Diagnostics - 2 year(s) ago
Brett King, MD, PhD, explains the altered screening and care strategies for patients following baricitinib’s approval.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
With the FDA approval of #baricitinib for #alopecia, dermatologists now have accomplished what one expert described as “the goal” for treating the common hair-loss condition. So what are the new goals for treatment? #FallClinical22 https://t.co/1v5lFF5tIC
-
This new research may aid health providers in advising patients on outcomes for those who could benefit from a higher dose of #baricitinib: https://t.co/anLd1UOQw7 #AlopeciaAreata #dermtwitter